Winson96 personal page - To The Moon

Winson96

Winson96

No personal profile

6Follow

1Followers

0Topic

0Badge

2021-09-16

Hi

Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month

2021-09-16

[Grin]

Sorry, the original content has been removed

2021-09-15

[Strong] [Strong] [Strong]

Moderna stock jumped 4% in morning trading

2021-09-12

Up up up, to the sky?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4089439192591850","uuid":"4089439192591850","gmtCreate":1626336372374,"gmtModify":1631496746002,"name":"Winson96","pinyin":"winson96","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":6,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":885181835,"gmtCreate":1631764947127,"gmtModify":1676530629935,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885181835","repostId":"1118309831","repostType":4,"repost":{"id":"1118309831","pubTimestamp":1631761632,"share":"https://ttm.financial/m/news/1118309831?lang=&edition=fundamental","pubTime":"2021-09-16 11:07","market":"us","language":"en","title":"Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1118309831","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking prof","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday further trimmed&nbsp;some of its stake&nbsp;in&nbsp;<b>Tesla</b>&nbsp;<b>Inc</b>, booking profits as the stock continued to show signs of recovery&nbsp;after months of dull performance this year.</p>\n<p>The popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in&nbsp;<b>the Elon Musk-</b>led company on Wednesday, its fourth such trade in Tesla in September.</p>\n<p>With the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.</p>\n<p>Tesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.</p>\n<p>Ark Invest deployed the&nbsp;<b>Ark Next Generation Internet ETF</b></p>\n<p>ARKW+undefined%and the&nbsp;<b>Ark Innovation ETF</b>ARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the A<b>rk Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ).</p>\n<p>The popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.&nbsp; Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.</p>\n<p>Tesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.</p>\n<p>Here are some of the other key trades for Ark on Wednesday:</p>\n<p>Bought 92,058 shares in&nbsp;<b>Robinhood Markets Inc</b></p>\n<p>Sold 2,398 shares in&nbsp;<b>Alphabet Inc</b></p>\n<p>Bought 538,680 shares in&nbsp;<b>UiPath Inc</b></p>\n<p>Sold 62,840 shares in&nbsp;<b>Iridium Communications Inc</b></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118309831","content_text":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in the Elon Musk-led company on Wednesday, its fourth such trade in Tesla in September.\nWith the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.\nTesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.\nArk Invest deployed the Ark Next Generation Internet ETF\nARKW+undefined%and the Ark Innovation ETFARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ).\nThe popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.  Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.\nTesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.\nHere are some of the other key trades for Ark on Wednesday:\nBought 92,058 shares in Robinhood Markets Inc\nSold 2,398 shares in Alphabet Inc\nBought 538,680 shares in UiPath Inc\nSold 62,840 shares in Iridium Communications Inc","news_type":1},"isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885183363,"gmtCreate":1631764806652,"gmtModify":1676530629912,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885183363","repostId":"2167592712","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882211215,"gmtCreate":1631694787837,"gmtModify":1676530610969,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882211215","repostId":"1118676828","repostType":4,"repost":{"id":"1118676828","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631631830,"share":"https://ttm.financial/m/news/1118676828?lang=&edition=fundamental","pubTime":"2021-09-14 23:03","market":"us","language":"en","title":"Moderna stock jumped 4% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118676828","media":"Tiger Newspress","summary":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine","content":"<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>\n <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>\n <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li>\n</ul>\n<p>A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p>\n<p>The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p>\n<p>Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p>\n<p>However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p>\n<p><b>Why Does Moderna Produce Higher Antibody Levels?</b></p>\n<p>According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p>\n<p>“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p>\n<p>The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p>\n<p>Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p>\n<p><b>Antibody Tests Don’t Tell the Whole Story</b></p>\n<p>The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p>\n<p>“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p>\n<p>A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p>\n<p>Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p>\n<p>Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p>\n<p>“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p>\n<p>A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p>\n<p>“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>\n <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>\n <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li>\n</ul>\n<p>A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p>\n<p>The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p>\n<p>Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p>\n<p>However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p>\n<p><b>Why Does Moderna Produce Higher Antibody Levels?</b></p>\n<p>According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p>\n<p>“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p>\n<p>The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p>\n<p>Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p>\n<p><b>Antibody Tests Don’t Tell the Whole Story</b></p>\n<p>The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p>\n<p>“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p>\n<p>A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p>\n<p>Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p>\n<p>Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p>\n<p>“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p>\n<p>A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p>\n<p>“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118676828","content_text":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\n\n\nA recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\nThis is possibly due to its higher mRNA content and a longer waiting period between doses.\nAntibody tests are not entirely predictive of the body’s immunity against COVID-19.\n\nA recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.\nThe August study, published in JAMA, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.\nAmong all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.\nHowever, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.\nWhy Does Moderna Produce Higher Antibody Levels?\nAccording to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.\n“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.\nThe Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.\nStill, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.\nAntibody Tests Don’t Tell the Whole Story\nThe study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.\n“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”\nA May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.\nAlthough antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.\nEarlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.\n“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”\nA March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.\n“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888158977,"gmtCreate":1631461211999,"gmtModify":1676530551647,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Up up up, to the sky?","listText":"Up up up, to the sky?","text":"Up up up, to the sky?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888158977","isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":882211215,"gmtCreate":1631694787837,"gmtModify":1676530610969,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882211215","repostId":"1118676828","repostType":4,"repost":{"id":"1118676828","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631631830,"share":"https://ttm.financial/m/news/1118676828?lang=&edition=fundamental","pubTime":"2021-09-14 23:03","market":"us","language":"en","title":"Moderna stock jumped 4% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118676828","media":"Tiger Newspress","summary":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine","content":"<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>\n <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>\n <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li>\n</ul>\n<p>A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p>\n<p>The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p>\n<p>Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p>\n<p>However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p>\n<p><b>Why Does Moderna Produce Higher Antibody Levels?</b></p>\n<p>According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p>\n<p>“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p>\n<p>The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p>\n<p>Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p>\n<p><b>Antibody Tests Don’t Tell the Whole Story</b></p>\n<p>The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p>\n<p>“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p>\n<p>A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p>\n<p>Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p>\n<p>Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p>\n<p>“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p>\n<p>A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p>\n<p>“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-14 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock jumped 4% in morning trading&nbsp;as&nbsp;a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li>\n <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li>\n <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li>\n</ul>\n<p>A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p>\n<p>The August study, published in&nbsp;<i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p>\n<p>Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p>\n<p>However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p>\n<p><b>Why Does Moderna Produce Higher Antibody Levels?</b></p>\n<p>According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p>\n<p>“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p>\n<p>The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p>\n<p>Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p>\n<p><b>Antibody Tests Don’t Tell the Whole Story</b></p>\n<p>The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p>\n<p>“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p>\n<p>A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p>\n<p>Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p>\n<p>Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p>\n<p>“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p>\n<p>A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p>\n<p>“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118676828","content_text":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\n\n\nA recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\nThis is possibly due to its higher mRNA content and a longer waiting period between doses.\nAntibody tests are not entirely predictive of the body’s immunity against COVID-19.\n\nA recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.\nThe August study, published in JAMA, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.\nAmong all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.\nHowever, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.\nWhy Does Moderna Produce Higher Antibody Levels?\nAccording to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.\n“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.\nThe Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.\nStill, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.\nAntibody Tests Don’t Tell the Whole Story\nThe study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.\n“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”\nA May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.\nAlthough antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.\nEarlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.\n“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”\nA March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.\n“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888158977,"gmtCreate":1631461211999,"gmtModify":1676530551647,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Up up up, to the sky?","listText":"Up up up, to the sky?","text":"Up up up, to the sky?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888158977","isVote":1,"tweetType":1,"viewCount":734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885181835,"gmtCreate":1631764947127,"gmtModify":1676530629935,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885181835","repostId":"1118309831","repostType":4,"repost":{"id":"1118309831","pubTimestamp":1631761632,"share":"https://ttm.financial/m/news/1118309831?lang=&edition=fundamental","pubTime":"2021-09-16 11:07","market":"us","language":"en","title":"Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1118309831","media":"Benzinga","summary":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking prof","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday further trimmed&nbsp;some of its stake&nbsp;in&nbsp;<b>Tesla</b>&nbsp;<b>Inc</b>, booking profits as the stock continued to show signs of recovery&nbsp;after months of dull performance this year.</p>\n<p>The popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in&nbsp;<b>the Elon Musk-</b>led company on Wednesday, its fourth such trade in Tesla in September.</p>\n<p>With the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.</p>\n<p>Tesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.</p>\n<p>Ark Invest deployed the&nbsp;<b>Ark Next Generation Internet ETF</b></p>\n<p>ARKW+undefined%and the&nbsp;<b>Ark Innovation ETF</b>ARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the A<b>rk Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ).</p>\n<p>The popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.&nbsp; Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.</p>\n<p>Tesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.</p>\n<p>Here are some of the other key trades for Ark on Wednesday:</p>\n<p>Bought 92,058 shares in&nbsp;<b>Robinhood Markets Inc</b></p>\n<p>Sold 2,398 shares in&nbsp;<b>Alphabet Inc</b></p>\n<p>Bought 538,680 shares in&nbsp;<b>UiPath Inc</b></p>\n<p>Sold 62,840 shares in&nbsp;<b>Iridium Communications Inc</b></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $61.7M Tesla Shares, Marking 4th Day Of Trimming Stake In Elon Musk Company This Month\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/news/21/09/22964062/cathie-wood-sells-another-61-7m-tesla-shares-marking-4th-day-of-trimming-stake-in-elon-musk-company","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118309831","content_text":"Cathie Wood-led Ark Invest on Wednesday further trimmed some of its stake in Tesla Inc, booking profits as the stock continued to show signs of recovery after months of dull performance this year.\nThe popular asset management firm sold 81,609 shares — estimated to be worth $61.7 million — in the Elon Musk-led company on Wednesday, its fourth such trade in Tesla in September.\nWith the latest sales, Ark Invest has trimmed a total of 354,181 shares — estimated to be worth about $267.7 million — in the Palo Alto, California-based company so far this month.\nTesla shares, which have risen about 6% since the beginning of this month, closed 1.52% higher at $755.83 a share on Wednesday. On a YTD basis, Tesla shares have risen about 3.57%.\nArk Invest deployed the Ark Next Generation Internet ETF\nARKW+undefined%and the Ark Innovation ETFARKK+undefined%to sell shares in Tesla. Ark Invest also owns shares in Tesla via the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ).\nThe popular New York-based investment management firm has a large exposure in Tesla, a stock it predicts will hit the$3,000 mark at the end of 2025.  Ark Invest has bought most of Tesla shares at far lower levels and Wood has said the firm isn't hesitant in booking profits on portfolio companies when they run up too high and then buy back at lower prices once they retreat.\nTesla ranks as the top-most-holding in each of the three ETFs and Ark held a total of 4.21 million shares — worth $3.13 billion — in the electric vehicle company, ahead of Wednesday’s trades. No other Ark ETF owns shares in Tesla.\nHere are some of the other key trades for Ark on Wednesday:\nBought 92,058 shares in Robinhood Markets Inc\nSold 2,398 shares in Alphabet Inc\nBought 538,680 shares in UiPath Inc\nSold 62,840 shares in Iridium Communications Inc","news_type":1},"isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885183363,"gmtCreate":1631764806652,"gmtModify":1676530629912,"author":{"id":"4089439192591850","authorId":"4089439192591850","name":"Winson96","avatar":"https://static.tigerbbs.com/ccaab866d210ccee630438cdf8ab4194","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089439192591850","authorIdStr":"4089439192591850"},"themes":[],"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885183363","repostId":"2167592712","repostType":4,"repost":{"id":"2167592712","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631747120,"share":"https://ttm.financial/m/news/2167592712?lang=&edition=fundamental","pubTime":"2021-09-16 07:05","market":"us","language":"en","title":"Wall Street gains as crude price surge, strong economic data prompt broad rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2167592712","media":"Reuters","summary":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted ","content":"<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street gains as crude price surge, strong economic data prompt broad rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street gains as crude price surge, strong economic data prompt broad rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-16 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SQQQ":"纳指三倍做空ETF","DXD":"道指两倍做空ETF","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","AAPL":"苹果","SDOW":"道指三倍做空ETF-ProShares","DJX":"1/100道琼斯","DDM":"道指两倍做多ETF","SDS":"两倍做空标普500ETF","LVS":"金沙集团","TQQQ":"纳指三倍做多ETF","GS":"高盛","QQQ":"纳指100ETF","DOG":"道指反向ETF","MGM":"美高梅","WYNN":"永利度假村","UPRO":"三倍做多标普500ETF","UDOW":"道指三倍做多ETF-ProShares","QID":"纳指两倍做空ETF","SH":"标普500反向ETF",".DJI":"道琼斯","IVV":"标普500指数ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167592712","content_text":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.\nAll three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.\nWhile value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .\n\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"\nA host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.\nImport prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.\nNext week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.\nThe graphic below shows major indicators against the Fed's average annual 2% inflation target.\nThe Dow Jones Industrial Average rose 236.82 points, or 0.68%, to 34,814.39; the S&P 500 gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite added 123.77 points, or 0.82%, at 15,161.53.\nAmong the 11 major sectors in the S&P 500, all but utilities gained ground. Energy was by far the biggest gainer, benefiting from a jump in crude prices driven by a drawdown in U.S. stocks.\nU.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd and MGM Resorts International slid between 1.7% and 6.3%.\nApple Inc snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.\nLending platform GreenSky Inc shot up 53.2% after Goldman Sachs Group Inc said it would buy the company in an all-stock deal valued at $2.24 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.\nThe S&P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}